Circulating Tumor DNA as a Prognostic and Predictive Biomarker in Lung Cancer

Area of Science:

• Oncology
• Molecular Diagnostics
• Cancer Research

Background:

• Lung cancer is a major global health concern, contributing significantly to cancer mortality.
• Liquid biopsy, specifically circulating tumor DNA (ctDNA) detection in blood, is an emerging tool in oncology.
• ctDNA analysis is particularly relevant for non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To review the current state of ctDNA technology in cancer diagnostics.
• To summarize the applications and limitations of ctDNA detection.
• To identify future research directions for ctDNA in oncology.

Main Methods:

• This study is a comprehensive literature review.
• The review focuses on ctDNA detection and its clinical utility.
• Key areas covered include detection, genotyping, prognostication, and therapy response evaluation.

Main Results:

• ctDNA detection is effective for various applications in NSCLC.
• Current uses include treatment selection, prognostication, and risk stratification.
• The technology demonstrates powerful current and potential benefits.

Conclusions:

• ctDNA analysis is a rapidly advancing field with significant clinical potential.
• Despite not being fully mature, ctDNA offers valuable insights for lung cancer management.
• Further research is needed to optimize ctDNA's role in personalized cancer care.